Eterna Therapeutics Inc. has appointed Sanjeev Luther as Chief Executive Officer, effective January 1, 2024. Mr. Luther will replace Matt Angel, Ph.D., the current Chief Executive Officer. Mr. Luther is a seasoned pharmaceutical executive having spent over 30 years in leadership roles across public and private biotechnology and global pharmaceutical companies.

Most recently, he served as President, CEO, and Board Member of Cornerstone Pharmaceuticals, where he oversaw the evolution of the company's pipeline for rare cancers and secured strategic partnership, in-licensing, and out-licensing agreements. At Cornerstone, he also held the roles of Chief Operations Officer and Chief Business Officer. Prior to Cornerstone, Mr. Luther led business-building and fundraising strategies for Fortune 500 corporations and start-ups in pharmaceuticals, biotech, medical devices, and diagnostics, including Bristol-Myers Squibb, Novartis, Bausch and Lomb, and GE Healthcare.

He has experience across a range of therapeutic areas and stages, from R&D through commercialization. Mr. Luther holds an MBA in Marketing and a B.S. in Marketing/Business Administration from the State University of New York at Buffalo.